ezetimibe (+) simvastatin
Drugezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
Other names: Vytorin®, MK0653A
NCT Number: NCT00651560
This study is intended to allow physicians to check the superior clinical efficacy of Vytorin compared to atorvastatin, as the most adequate therapy using the ATP-III goals achievement and cardiovascular risk reduction in adult patients with dislipidemia.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
Other names: Vytorin®, MK0653A
Time frame: After 4 weeks treatment
Time frame: After 4 weeks treatment
Organon and Co
Industry
Vytorin As Strategy To Reduce Dislipidemia In Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07710898
Diabete Mellitus, Diabetes Mellitus
Lahore, Pakistan
View Trial DetailsNCT07696559
Dyslipidemias, Hyperlipidemia
Lahore, Pakistan
View Trial DetailsNCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial DetailsNCT01212159
Dyslipidemias, Hyperlipidemia
Philadelphia, Pennsylvania, United States
View Trial Details